FDA Inspection
Bioreliance CorporationBioreliance Corporation – FDA Inspection, Nov 22, 2024
Record Details
This FDA Inspection record concerns Bioreliance Corporation, with an inspection on November 22, 2024, issued by the Baltimore District Office, covering biologics.
View Company Profile
ID · 7941bc6b-db19-4266-b05d-af8a19fbde51
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1254934
- FDA center
- Biologics
- Project area
- Vaccine, Allergenic, and Live Biotherapeutic Products
FDA Citations
1- 21 CFR 211.192Investigations of discrepancies, failures
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Bioreliance Corporation
11| Date | Classification | Office | Project area |
|---|---|---|---|
| January 29, 2026 | VAI | Baltimore District Office | Bioresearch Monitoring: Human Drugs |
| August 4, 2023 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| August 8, 2019 | Not classified | Baltimore District Office | |
| July 13, 2018 | VAI | Center for Biologics Evaluation and Research | Vaccines and Allergenic Products |
| January 11, 2016 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Bioreliance Corporation
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.